 | Up a level |
Journal Article
Gaidano, G., Platzbecker, U., Kreuzer, K. -A., Bernal de Castillo, T., Silverman, L., Garcia-Manero, G., Loferer, H. and Fenaux, P. (2015). SUBGROUP ANALYSES OF A PHASE 3 STUDY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES FAILING HMA TREATMENT: IDENTIFICATION OF A HOMOGENEOUS POPULATION WHO BENEFIT FROM RIGOSERTIB THERAPY. Haematologica, 100. S. 491 - 493. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Garcia-Manero, G., Fenaux, P., Al-Kali, A., Baer, M., Sekeres, M., Roboz, G., Gaidano, G., Scott, B., Greenberg, P., Platzbecker, U., Steensma, D., Kreuzer, K. -A., Godley, L., Collins, R., Atallah, E., Azarnia, N. and Silverman, L. (2015). OVERALL SURVIVAL (OS) AND BASELINE DISEASE CHARACTERISTICS IN MDS PATIENTS WITH PRIMARY HMA FAILURE IN A RANDOMIZED, CONTROLLED, PHASE III STUDY OF RIGOSERTIB. Haematologica, 100. S. 238 - 239. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Silverman, L., Fenaux, P., Al-Kali, A., Baer, M., Sekeres, M., Roboz, G., Gaidano, G., Scott, B., Greenberg, P., Platzbecker, U., Steensma, D., Kreuzer, K. -A., Godley, L., Collins, R., Atallah, E., Azarnia, N. and Garcia-Manero, G. (2015). PROGNOSTIC AND PREDICTIVE VALUE OF IPSS-R IN ASSESSING OVERALL SURVIVAL (OS) IN A PHASE III STUDY OF RIGOSERTIB IN SECOND-LINE HIGHER-RISK (HR) MDS PATIENTS. Haematologica, 100. S. 492 - 493. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078